Former Chief Financial Officer · Xeris Biopharma Holdings, Inc. (XERS)

Barry Deutsch

FY2021 is the first fiscal year CompBrief holds for Barry Deutsch as a named executive officer of Xeris Biopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,799,120

Salary $318,847Stock awards $584,200

2nd of 4 named executive officers at Xeris Biopharma by FY2021 total.

4 named officers on file for Xeris Biopharma, FY2021

Barry Deutsch’s pay file — $29

  • 1 fiscal year of pay, line by line
  • XERS’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Xeris Biopharma’s whole pay program stands against its peers

  • Xeris Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XERS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Barry Deutsch’s full pay file as a PDF — free

More than this page: up to 10 years of Barry’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Barry Deutsch compensation by year

Xeris Biopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Xeris Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$318,847
Bonus$0
Stock awards$584,200
Option awards$0
Non-equity incentive$169,158
Pension and deferred compensation$0
All other$726,915
Total$1,799,120

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xeris Biopharma Holdings, Inc. DEF 14A filed April 28, 2022, accession 0001867096-22-000047, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Xeris Biopharma Holdings, Inc. filed document, accession 0001867096-22-000047. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Xeris Biopharma’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Paul EdickChief Executive Officer$3,764,134
Barry Deutsch · this pageFormer Chief Financial Officer$1,799,120
John ShannonPresident and Chief Operating Officer$1,728,640
Beth HechtChief Legal Officer and Corporate Secretary$1,424,994

The full Xeris Biopharma compensation record

free company brief

This page is one person within Xeris Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xeris Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Barry Deutsch's compensation dossier · One-time report. No refunds.